Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
What does me being happy have to do with your false info?
Are you every big investor's spokesperson?
You say you're hopeful and wish me luck but I take that as I do with all forward leading comments on bull boards, maybe true, maybe not true. I'm leaning toward the latter.
The onus is on the buyer, not the Bunka! Bunka has never promised anything because he knows better. Insiders can only legally say what they think may or may not come true. Investors and traders need to read between the lines and listen more carefully to exactly what is said. Also, read the disclaimers titled "Caution regarding forward looking statements" on all the news releases and on any news release for any publicly owned company for that matter.
Here's one from one of the latest Lexaria news releases:
"This press release includes forward-looking statements. Statements as such term is defined under applicable securities laws. These statements may be identified by words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions. Such forward-looking statements in this press release include, but are not limited to, statements by the company relating the Company's ability to carry out research initiatives, receive regulatory approvals or grants or experience positive effects or results from any research or study. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that the Company will actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements. As such, you should not place undue reliance on these forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH technology, the Company's ability to maintain existing collaborations and realize the benefits thereof, delays or cancellations of planned R&D that could occur related to pandemics or for other reasons, and other factors which may be identified from time to time in the Company's public announcements and periodic filings with the US Securities and Exchange Commission on EDGAR. There is no assurance that any of Lexaria's postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease. Any forward-looking statements contained in this release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law".
Harlem - Your comments are all negative, completely out of context and mostly untrue. For someone who hopes for the best outcome in the stock, you sure have a funny way of inspiring new investors. Perhaps some comments re: all the great studies being done and extremely positive future we have. To help you out I have posted a link to Lexaria's News Release history. Things are actually a lot better than you portend. https://ir.lexariabioscience.com/news-events/press-releases
DehydraTECH making news.New Hill Street deal in the States. https://ceo.ca/@newsfile/hill-street-announces-major-new-us-dehydratechtm
You'll be correct until you're not.
Altria has never said they are in or out.
Altria owns part of Lexaria's nicotine subsidiary and although they have lost their exclusivity in the US they still have an agreement with LEXX to pay royalties for any product they sell that uses Dehydratech. They could sign back on to make a new product or use us in an existing one any time they want.
The Senate on Thursday unanimously approved a marijuana bill—but not the federal legalization measure that advocates have been eagerly awaiting Senate Majority Leader Chuck Schumer (D-NY) to bring to the floor. Rather, it’s a modest bipartisan piece of legislation that’s simply meant to promote research into marijuana.
The bill—sponsored by Sens. Dianne Feinstein (D-CA), Brian Schatz (D-HI) and Chuck Grassley (R-IA)—is titled the Cannabidiol and Marihuana Research Expansion Act. It cleared the full chamber unanimously, without debate.
It would streamline the application process for researchers who want to study the plant and to encourage the Food and Drug Administration (FDA) to develop cannabis-derived medicines.
It would also clarify that physicians are allowed to discuss the risks and benefits of marijuana with patients and require the U.S. Department of Health and Human Services (HHS) to submit a report on those potential health benefits, as well one on barriers to cannabis research and how to overcome those obstacles.
“Current rules and regulations make it hard for researchers to study how marijuana and marijuana-derived medications can best be used to treat various conditions,” Feinstein said in a press release. “This important legislation will cut the red-tape around the research process, helping get FDA-approved, marijuana-derived medications safely to patients.”
https://www.marijuanamoment.net/u-s-senate-unanimously-approves-marijuana-reform-bill-on-same-day-that-house-schedules-legalization-vote/#:~:text=News%3A%20This%20Senate%20just%20unanimously,encourage%20federal%20research%20into%20CBD.&text=The%20bill's%20other%20original%20cosponsors,Klobuchar%20(D%2DMN).
News: This Senate just unanimously passed a bill to expand scientific and medical research on cannabis and encourage federal research into CBD.
News: This Senate just unanimously passed a bill to expand scientific and medical research on cannabis and encourage federal research into CBD.
— Chuck Schumer (@SenSchumer) March 24, 2022
You'll never know what does and doesn't happen behind closed doors. Only what does and becomes a news release! Investors have to take forward comments with grains of salt, just like I choose to do with board comments about how Bunka is failing us. For all we know he will pull the proverbial rabbit out of his hat, make a huge tobacco/ pharma deal and make liars out of the majority of us. Hang in there.
Thanks Shawking. Here's a link to the interview: https://4495825a-d729-4d8f-ade8-e78f828e1c8d.usrfiles.com/ugd/449582_1c51d72b705e445ea8563b2b6091e0e5.pdf
Time to accumulate again eh?
Hill Street update https://ceo.ca/@newswire/hill-street-provides-business-update-at-one-year-mark
"Currently, Michigan has purchase orders to produce over 20 million milligrams of DehydraTECH™ through March 2022 for infusion into form factors including powder mixes, gummy edibles and topicals for both the medical use and adult use markets".
If LEXX sold for 500M we'd all be laughing.
Are you new to the market?
No insiders on LEXX sell their shares. You should know this as an investor.
You can sell yours for a dollar if you want!
Altria and all the large tobacco companies are trying to move away from tobacco products. The heat, not burn category is one they have been leaning on heavily as a revenue source. Now this revenue is being taken away from them so it would follow that Altria and PM will be even more pressed than before to find alternative nicotine products to make revenue from. The partnership with LEXX from a few years ago has so far not seemed to help LEXX much but Altria still owns part of our Nicotine subsidiary, still has a royalties agreement with LEXX and we've continued to make strides towards finding better ways to deliver nicotine.
All tobacco companies are constantly on the hunt for the kind of tech LEXX has and when the moment is right, one of them will make that move. This is one more major reason for a large tobacco company to knock on Lexaria's door.
The ban would have been just implemented.
"The import and sales ban will take effect in two months after an administrative review".
Hill Street doubles revenues https://www.newsfilecorp.com/release/105518
MD Financial 8% owner of LEXX (as of in the last few months) must have noticed some value in LEXX or they wouldn't have just bought over 400,000 shares.
I don't suppose they got where they are by buying companies that just waste their money? Do you?
https://mdm.ca/md-financial-management?gclid=CjwKCAiAs92MBhAXEiwAXTi25_gNJx2eTEiFgrW5SBIHl9gCK6Vd2DJWrbzU72PCoYZzRC_ToEZ9WxoCMoIQAvD_BwE&gclsrc=aw.ds
I encourage folks to read all the great post history of harlem111.
If you don't like it, sell it and quit whining.
Better than mine, I'm sure!
Bunka never owned more than he does now.
MD Financial institutional owns approx. 8% of LEXX (407,687 shares) according to this website: https://whalewisdom.com/stock/lexx
Other notable owners are:
Chris Bunka with 489,455 shares (9.6%)
Invenomic Capital Management 353,419 shares (6.9%)
L1 Capital 285,727 shares (5.6%)
Not sure if these are exact. I found the same numbers on two different sites.
This is some great publicity for DehydraTECH and building up revenue for Hill Street helps increase the value of the Hill Street shares we own. Here's the new website link to the new THC pouch flavours and strengths. Looks pretty awesome! https://cannadipsthc.com/
The employees are doing all the work to try better the company and deserve the perks of doing so. What have you done for us all? This is what happens at all public companies. Perhaps doing some due diligence before investing would be a prudent idea.
Patience people. We have a great tech that can be put into service any day in many different ways. When that big fish comes calling we'll hopefully be laughing all the way to the bank. With big risk comes big reward. Hang tight all. :)
LOL No doubt. Some pharma interest/LOI's/deals would go a long way right now.
Gap up time tomorrow?